Cargando…
Overexpression of Eag1 potassium channels in clinical tumours
BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1621079/ https://www.ncbi.nlm.nih.gov/pubmed/17022810 http://dx.doi.org/10.1186/1476-4598-5-41 |
_version_ | 1782130551482744832 |
---|---|
author | Hemmerlein, Bernhard Weseloh, Rüdiger M Mello de Queiroz, Fernanda Knötgen, Hendrik Sánchez, Araceli Rubio, María E Martin, Sabine Schliephacke, Tessa Jenke, Marc Heinz-Joachim-Radzun Stühmer, Walter Pardo, Luis A |
author_facet | Hemmerlein, Bernhard Weseloh, Rüdiger M Mello de Queiroz, Fernanda Knötgen, Hendrik Sánchez, Araceli Rubio, María E Martin, Sabine Schliephacke, Tessa Jenke, Marc Heinz-Joachim-Radzun Stühmer, Walter Pardo, Luis A |
author_sort | Hemmerlein, Bernhard |
collection | PubMed |
description | BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects. |
format | Text |
id | pubmed-1621079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-16210792006-10-24 Overexpression of Eag1 potassium channels in clinical tumours Hemmerlein, Bernhard Weseloh, Rüdiger M Mello de Queiroz, Fernanda Knötgen, Hendrik Sánchez, Araceli Rubio, María E Martin, Sabine Schliephacke, Tessa Jenke, Marc Heinz-Joachim-Radzun Stühmer, Walter Pardo, Luis A Mol Cancer Research BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects. BioMed Central 2006-10-05 /pmc/articles/PMC1621079/ /pubmed/17022810 http://dx.doi.org/10.1186/1476-4598-5-41 Text en Copyright © 2006 Hemmerlein et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Hemmerlein, Bernhard Weseloh, Rüdiger M Mello de Queiroz, Fernanda Knötgen, Hendrik Sánchez, Araceli Rubio, María E Martin, Sabine Schliephacke, Tessa Jenke, Marc Heinz-Joachim-Radzun Stühmer, Walter Pardo, Luis A Overexpression of Eag1 potassium channels in clinical tumours |
title | Overexpression of Eag1 potassium channels in clinical tumours |
title_full | Overexpression of Eag1 potassium channels in clinical tumours |
title_fullStr | Overexpression of Eag1 potassium channels in clinical tumours |
title_full_unstemmed | Overexpression of Eag1 potassium channels in clinical tumours |
title_short | Overexpression of Eag1 potassium channels in clinical tumours |
title_sort | overexpression of eag1 potassium channels in clinical tumours |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1621079/ https://www.ncbi.nlm.nih.gov/pubmed/17022810 http://dx.doi.org/10.1186/1476-4598-5-41 |
work_keys_str_mv | AT hemmerleinbernhard overexpressionofeag1potassiumchannelsinclinicaltumours AT weselohrudigerm overexpressionofeag1potassiumchannelsinclinicaltumours AT mellodequeirozfernanda overexpressionofeag1potassiumchannelsinclinicaltumours AT knotgenhendrik overexpressionofeag1potassiumchannelsinclinicaltumours AT sanchezaraceli overexpressionofeag1potassiumchannelsinclinicaltumours AT rubiomariae overexpressionofeag1potassiumchannelsinclinicaltumours AT martinsabine overexpressionofeag1potassiumchannelsinclinicaltumours AT schliephacketessa overexpressionofeag1potassiumchannelsinclinicaltumours AT jenkemarc overexpressionofeag1potassiumchannelsinclinicaltumours AT heinzjoachimradzun overexpressionofeag1potassiumchannelsinclinicaltumours AT stuhmerwalter overexpressionofeag1potassiumchannelsinclinicaltumours AT pardoluisa overexpressionofeag1potassiumchannelsinclinicaltumours |